Watson Is Bullish On Launching Enhanced Ferrlecit Generic Soon
This article was originally published in The Pink Sheet Daily
Executive Summary
Watson's own citizen petitions blocking generics won't be an obstacle, company says.
You may also be interested in...
Ferrlecit Generic To Get 3-Part Evaluation After FDA Worry On Therapeutic Equivalence
Actavis’ version of Sanofi’s brand comes under scrutiny after EU guidance suggests generic iron formulations could have higher levels of labile iron and that study of plasma levels alone “may conceivably fail to detect relevant differences in the tissue distribution of iron.”
AMAG Pharmaceuticals: Enough Irons In The Fire?
Demand for AMAG’s newly launched Feraheme has been robust but a changing reimbursement climate, especially in the dialysis market, complicates the product’s pricing strategy, and puts increased pressure on management to diversify via dealmaking.
AMAG Pharmaceuticals: Enough Irons In The Fire?
Demand for AMAG’s newly launched Feraheme has been robust but a changing reimbursement climate, especially in the dialysis market, complicates the product’s pricing strategy, and puts increased pressure on management to diversify via dealmaking.